Estrella Immunopharma, Inc. Quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD from Q3 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
Estrella Immunopharma, Inc. quarterly Deferred Tax Assets, Operating Loss Carryforwards history and growth rate from Q3 2021 to Q2 2024.
  • Estrella Immunopharma, Inc. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending June 30, 2024 was $1.84M, a 418% increase year-over-year.
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $1.84M +$1.48M +418% Jun 30, 2024 10-K 2024-09-27
Q2 2023 $355K +$198K +126% Jun 30, 2023 10-K 2024-09-27
Q4 2022 $0 -$52K -100% Dec 31, 2022 10-K 2023-03-14
Q3 2022 $230K +$206K +877% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $157K Jun 30, 2022 10-Q 2022-08-08
Q1 2022 $81.7K Mar 31, 2022 10-Q 2022-05-16
Q4 2021 $52K Dec 31, 2021 10-K 2023-03-14
Q3 2021 $23.5K Sep 30, 2021 10-Q 2021-11-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.